The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

Ultomiris is a longer lasting version of Alexion’s Soliris (eculizumab) complement inhibitor, which has produced “promising” evidence in the clinic through a compassionate use programme ...

NICE and Alexion not backing down The Soliris appraisal has largely been conducted via complex health economic arguments and counter arguments, but NICE's HST committee and representatives came ...

approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti ...

The story is unbranded, but Alexion is the maker of aHUS treatments Soliris and its newer, upgraded sibling Ultomiris, to which Soliris patients are encouraged to switch. AstraZeneca's Alexion ...

Alexion, AstraZeneca Rare Disease has received ... treatment with C5 inhibitors such as Ultomiris (ravulizumab) or Soliris (eculizumab). The FDA’s decision is grounded in the positive outcomes ...

Alexion CEO Marc Dunoyer stated ... Ultomiris was benchmarked against an external placebo group from the Soliris PREVENT clinical trial. The primary endpoint of time to first on-trial relapse ...

Market Research Report for 2025 delivers a comprehensive analysis of the industry's progress, examining both historical trends and the current market landscape. It provides key insights into ...